A major medical university and a patient group for a common cardiac disease are two of the recent groups to come out in support of the Association for Molecular Pathology's CLIA-heavy legislative proposal for regulation of laboratory developed tests, according to letters sent to the Senate health committee obtained by Inside Health Policy . This comes as Senate Republican staffers recently visited with key stakeholder organizations and urged them to send letters of support for legislative action, as FDA continues...